Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVRI · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| EVRI (BMS-690514) | DRUG | Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay |
Inclusion Criteria: * Healthy male subjects * Body mass index (BMS) of 18 - 30 kg/m², inclusive Exclusion Criteria: * Radiation exposure from diagnostic X-rays (except dental X-rays) in the last year or from clinical trials in the last 5 years
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
EVRI is an investigational small molecule being developed by Bristol-Myers Squibb Company (BMY) for the treatment of cancer. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under study to evaluate its safety and pharmacokinetics.
EVRI is being studied for use in cancer. It is an investigational oncology small molecule, and its clinical development program includes a Phase 1 trial focused on evaluating the pharmacokinetics and metabolism of the drug in healthy subjects, which is a step toward understanding how it may be used in cancer treatment.
EVRI is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the stock exchange under the ticker symbol BMY. The company is conducting clinical research on this investigational oncology small molecule.
EVRI is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied in early-stage trials to assess its pharmacokinetics and metabolism. The single completed Phase 1 trial enrolled 17 participants.
EVRI has one completed Phase 1 clinical trial, identified as NCT00578916, titled "Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects." This uncontrolled, non-randomized study enrolled 17 healthy male volunteers in Switzerland and was not biomarker-selected.